ClinicalTrials.Veeva

Menu
A

Amicis Research Center | Northridge, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Lorundrostat
IMG-007
Dapagliflozin
BION-1301
SAR443765
Zanubrutinib
Bardoxolone Methyl

Parent organization

This site is a part of Amicis Research Center

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 10 total trials

A Study to Evaluate the Safety and Efficacy of Zanubrutinib in Participants With Primary Membranous Nephropathy

The primary objectives of this study are: In Part 1 to evaluate the efficacy of zanubrutinib as measured by proteinuria reduction, and in Part 2 to e...

Enrolling
Primary Membranous Nephropathy
Drug: Tacrolimus
Drug: Zanubrutinib
Locations recently updated

This is a Phase 2b, global, multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the efficacy, saf...

Enrolling
Asthma
Drug: Placebo
Drug: Lunsekimig

This is a randomized, double-blind (DB), placebo controlled, crossover study with a two-period, two-sequence (2x2) design evaluating the efficacy and...

Enrolling
Chronic Kidney Disease
Drug: Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD
Drug: Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD

This is a Phase 3 trial to evaluate the BP-lowering effect of lorundrostat (an aldosterone synthase inhibitor) in subjects with uncontrolled and resi...

Enrolling
Hypertension
Drug: Placebo
Drug: lorundrostat Dose 2

Multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of BION-1301 in healthy volunteers...

Active, not recruiting
IgA Nephropathy
Drug: BION-1301 Multiple Doses
Drug: Placebo Multiple Doses

Trial sponsors

Amgen logo
M
BeiGene logo
B
C
I
Reata Pharmaceuticals logo
Sanofi logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems